Fecal Microbiota Transplantation for Treatment of Acute Graft-versus-Host Disease
Peer review is under the responsibility of IACH
- https://doi.org/10.2991/chi.d.190316.002How to use a DOI?
- Hematopoietic stem cell transplantation, Graft-versus-host disease, Microbiome, Fecal microbiota transplantation
The growing understanding of the bidirectional relationship between the gastrointestinal (GI) microbiome and the immune system has opened up new avenues for treatment of graft-versus-host disease (GVHD). Fecal microbiota transplantation (FMT) is the transfer of stool from a donor to a recipient who harbors a perturbed GI microbiome resulting in disease. We review the rationale for performing FMT for the treatment of acute GVHD, and summarize data on the safety and efficacy of the procedure among allogeneic hematopoietic stem cell transplantation (HSCT) recipients. Overall, FMT is a promising strategy in treating and preventing HSCT-related complications. However, caution should be exerted as HSCT recipients are highly immunosuppressed and unanticipated infectious adverse events may appear with the increasing application of FMT.
- © 2019 International Academy for Clinical Hematology. Publishing services by Atlantis Press International B.V.
- Open Access
- This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).
Cite this article
TY - JOUR AU - Roni Shouval AU - Mika Geva AU - Arnon Nagler AU - Ilan Youngster PY - 2019 DA - 2019/04/18 TI - Fecal Microbiota Transplantation for Treatment of Acute Graft-versus-Host Disease JO - Clinical Hematology International SP - 28 EP - 35 VL - 1 IS - 1 SN - 2590-0048 UR - https://doi.org/10.2991/chi.d.190316.002 DO - https://doi.org/10.2991/chi.d.190316.002 ID - Shouval2019 ER -